Search Result

Results for "

estrogen receptor modulator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Estrogen Receptor/ERR (113) 17β-HSD (1) Adhesion G Protein-coupled Receptors (AGPCRs) (1) Akt (3) Aldose Reductase (1) Apoptosis (22) Aryl Hydrocarbon Receptor (1) Autophagy (10) Bcl-2 Family (1) Caspase (2) COX (4) Cytochrome P450 (1) Dengue Virus (2) Drug Intermediate (1) Drug Metabolite (3) Endogenous Metabolite (8) Flavivirus (2) Glucocorticoid Receptor (1) HSP (9) Isotope-Labeled Compounds (23) LXR (2) MELK (1) MMP (1) NO Synthase (3) PKC (2) Reactive Oxygen Species (ROS) (2) Reference Standards (17) VEGFR (1)
By Research Areas:	Cancer (84) Cardiovascular Disease (8) Endocrinology (38) Infection (10) Inflammation/Immunology (8) Metabolic Disease (12) Neurological Disease (8)
Oligonucleotides:	Cholesterol (1)

118

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Estrogen Receptor/ERR

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-16950

4-Hydroxytamoxifen 50+ Cited Publications (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene	Estrogen Receptor/ERR	Cancer
4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .

HY-13757

Tamoxifen Citrate Maximum Cited Publications 229 Publications Verification ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice .

HY-16950A

(E/Z)-4-Hydroxytamoxifen 3 Publications Verification Afimoxifene; 4-OHT	Estrogen Receptor/ERR Adhesion G Protein-coupled Receptors (AGPCRs) Drug Metabolite	Metabolic Disease Cancer
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective **estrogen receptor** modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity .

HY-N2371

27-Hydroxycholesterol 5+ Cited Publications 27-OHC	Estrogen Receptor/ERR LXR Endogenous Metabolite	Cancer
27-Hydroxycholesterol (27-OHC) is a selective **estrogen receptor** modulator and an agonist of the liver X receptor.

HY-A0036

Bazedoxifene acetate 15+ Cited Publications TSE-424 acetate	Estrogen Receptor/ERR	Cancer
Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130** protein-protein interactions and can be used for the research of pancreatic cancer .

HY-A0031

Bazedoxifene 15+ Cited Publications TSE-424	Estrogen Receptor/ERR	Neurological Disease Cancer
Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130** protein-protein interactions and can be used for the research of pancreatic cancer .

HY-13738A

Raloxifene hydrochloride Maximum Cited Publications 19 Publications Verification Keoxifene hydrochloride; LY156758; LY139481 hydrochloride	Estrogen Receptor/ERR Autophagy	Endocrinology Cancer
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-B0463

Clomiphene citrate 5 Publications Verification Clomifene citrate	Estrogen Receptor/ERR	Neurological Disease Endocrinology Cancer
Clomiphene citrate (Clomifene citrate) is an orally active **estrogen-receptor modulator**. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .

HY-13738

Raloxifene 15+ Cited Publications Keoxifene; LY156758 free base; LY139481	Estrogen Receptor/ERR	Cancer
Raloxifene (Keoxifene) is a benzothiophene-derived selective **estrogen receptor** modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-B0723

Ospemifene 2 Publications Verification FC-1271a	Estrogen Receptor/ERR Caspase	Neurological Disease Endocrinology Cancer
Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with K_i values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .

HY-103454

MPP dihydrochloride 15+ Cited Publications	Estrogen Receptor/ERR Apoptosis	Endocrinology Cancer
MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .

HY-B0005A

Toremifene 5+ Cited Publications Z-Toremifene; NK 622 free base; FC-1157a free base	Estrogen Receptor/ERR	Infection Cancer
Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-A0037

Lasofoxifene 5 Publications Verification CP-336156	Estrogen Receptor/ERR	Inflammation/Immunology Cancer
Lasofoxifene (CP-336156) is an orally active and selective **estrogen receptor** modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .

HY-15731

Estetrol	Estrogen Receptor/ERR Endogenous Metabolite NO Synthase	Cardiovascular Disease Cancer
Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-B0005

Toremifene citrate 5+ Cited Publications Z-Toremifene citrate; NK 622; FC-1157a	Estrogen Receptor/ERR Apoptosis	Infection Cancer
Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 μM and 2.6 μM, respectively .

HY-13724B

Pipendoxifene hydrochloride	Estrogen Receptor/ERR	Cancer
Pipendoxifene hydrochloride is a selective **estrogen receptor** modulator (SERM) that can be used for the research of breast cancer .

HY-W011100

Cyclofenil	Dengue Virus Estrogen Receptor/ERR Flavivirus	Infection Endocrinology
Cyclofenil is a selective **estrogen receptor** modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC₅₀ of 1.62 μM. Cyclofenil has anti-dengue-virus activity .

HY-103454B

MPP hydrochloride 15+ Cited Publications	Estrogen Receptor/ERR Apoptosis	Endocrinology Cancer
MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .

HY-A0038

Lasofoxifene tartrate 5 Publications Verification CP-336156 tartrate	Estrogen Receptor/ERR	Endocrinology Cancer
Lasofoxifene (CP-336156) tartrate is an orally active and selective **estrogen receptor** modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .

HY-16950B

(E)-4-Hydroxytamoxifen (E)-Afimoxifene	Estrogen Receptor/ERR	Cancer
(E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an **estrogen receptor** modulator.

HY-126109

(±)-8-Prenylnaringenin	Estrogen Receptor/ERR Apoptosis	Metabolic Disease Endocrinology Cancer
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen *Receptor/ERR) that inhibits ERα* and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-135582

Raloxifene 4'-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to **estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor** modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-110201

Estrogen receptor modulator 1	Estrogen Receptor/ERR	Cancer
Estrogen receptor modulator 1 (compound 18) is an orally active and selective **estrogen receptor** modulator (SERM), with a pIC₅₀ of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .

HY-13556A

Arzoxifene hydrochloride 1 Publications Verification LY353381 hydrochloride; SERM III hydrochloride	Estrogen Receptor/ERR	Cancer
Arzoxifene (LY353381) hydrocloride is a selective **estrogen receptor** modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.

HY-B2158

Chlorotrianisene	Estrogen Receptor/ERR COX	Cardiovascular Disease Endocrinology
Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood .

HY-13757AS

Tamoxifen-d5 ICI 47699-d5; (Z)-Tamoxifen-d₅; trans-Tamoxifen-d₅	Isotope-Labeled Compounds Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity .

HY-121149

Droloxifene 1 Publications Verification 3-Hydroxytamoxifen	Estrogen Receptor/ERR Apoptosis	Cancer
Droloxifene, a Tamoxifen derivative, is an orally active and selective **estrogen receptor** modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .

HY-A0036D

Bazedoxifene acetate-D TSE-424 acetate-D	Estrogen Receptor/ERR	Cancer
Bazedoxifene (acetate)-D (TSE-424 (acetate)-D) is the D-crystal form compound of Bazedoxifene acetate (HY-A0036). Bazedoxifene acetate is an orally active, nonsteroidal selective estrogen receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively .

HY-13724

Pipendoxifene ERA-923	Estrogen Receptor/ERR	Cancer
Pipendoxifene is a selective **estrogen receptor** modulator (SERM).

HY-U00178

Idoxifene CB7432	Estrogen Receptor/ERR	Cancer
Idoxifene (CB7432) is a novel tissue-specific selective **estrogen receptor** modulator (SERM).

HY-13738AR

Raloxifene hydrochloride (Standard) 5+ Cited Publications Keoxifene hydrochloride(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)	Reference Standards Estrogen Receptor/ERR Autophagy	Endocrinology Cancer
Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-164764

ADX61623	Estrogen Receptor/ERR	Endocrinology
ADX61623 is a potent *follicle stimulating hormone (FSH) receptor* (FSHR)** negative allosteric modulator (NAM). ADX61623 shows luteinizing hormone receptor (LH-R) activity and is not active on thyroid-stimulating hormone (TSH) receptors. ADX61623 can be used for the study of estrogen dependent disease .

HY-A0031A

Bazedoxifene hydrochloride TSE-424 hydrochloride	Estrogen Receptor/ERR	Cancer
Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130** protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer .

HY-A0036R

Bazedoxifene acetate (Standard) TSE-424 acetate (Standard)	Reference Standards Estrogen Receptor/ERR	Cancer
Bazedoxifene (acetate) (Standard) is the analytical standard of Bazedoxifene (acetate). This product is intended for research and analytical applications. Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal *selective estrogen* receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130** protein-protein interactions and can be used for the research of pancreatic cancer .

HY-N2371R

27-Hydroxycholesterol (Standard) 27-OHC (Standard)	Reference Standards Estrogen Receptor/ERR LXR Endogenous Metabolite	Cancer
27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the liver X receptor.

HY-13556

Arzoxifene LY353381; SERM III	Estrogen Receptor/ERR	Metabolic Disease Cancer
Arzoxifene (LY353381) is an orally active selective **estrogen receptor** modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile .

HY-79576

Estrone 3-methyl ether Oestrone methyl ether; 3-O-Methylestrone	Drug Intermediate	Cancer
Estrone 3-methyl ether (Oestrone methyl ether; 3-O-Methylestrone) is a synthetic intermediate useful for synthesis of estrogen receptor modulator .

HY-16950BS

(E)-4-Hydroxytamoxifen-d5 (E)-Afimoxifene-d₅	Isotope-Labeled Compounds Estrogen Receptor/ERR	Cancer
(E)-4-Hydroxytamoxifen-d5 ((E)-Afimoxifene-d5) is the deuterium labeled (E)-4-Hydroxytamoxifen. (E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an **estrogen receptor** modulator.

HY-B0463R

Clomiphene citrate (Standard) Clomifene citrate (Standard)	Reference Standards Estrogen Receptor/ERR	Neurological Disease Endocrinology Cancer
Clomiphene (citrate) (Standard) is the analytical standard of Clomiphene (citrate). This product is intended for research and analytical applications. Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .

HY-N11785

Glyceollin I	Estrogen Receptor/ERR	Metabolic Disease Cancer
Glyceollin I is a selective estrogen receptor (ER) modulator with anticancer, antioxidant, and anti-inflammatory activities. Glyceollin I is promising for research of estrogen-related cancers (e.g., breast, ovarian) and metabolic disorders (e.g., hypercholesterolemia) .

HY-138690

Estrogen receptor modulator 6	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor modulator 6 (compound 3a) is a selective estrogen receptor (ER) β agonist (K_i=0.44 nM). Estrogen receptor modulator 6 displays 19-fold selectivity for ERβ over ERα(K_i=8.4 nM) .

HY-153700

Estrogen receptor modulator 8	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor modulator 8 (compound 4) is an orally active inhibitor of Estrogen Receptor/ERR α (IC₅₀=0.437 nM, MCF-7 cells). Estrogen receptor modulator 8 inhibits MCF-7 cells proliferation with an IC₅₀ value of 0.1 nM .

HY-155406

Estrogen receptor modulator 10	Estrogen Receptor/ERR Caspase Bcl-2 Family	Cancer
Estrogen receptor modulator 10 (compound G-5b) is an estrogen receptor (ER) antagonist (IC₅₀=6.7 nM) and degrader (DC₅₀=0.4 nM). Estrogen receptor modulator 10 is developed based on the Fulvestrant (HY-13636) molecule and can rapidly degrade ER receptors through the proteasome pathway. Estrogen receptor modulator 10 can induce cell apoptosis and block cells in the G1/G0 phase and can be used in cancer research .

HY-114154

AL-438	Glucocorticoid Receptor	Inflammation/Immunology
AL-438 is a potent, selective and orally active glucocorticoid receptor modulator with K_is of 2.5, 1786, 53, 1440, >1000 nM for glucocorticoid receptor, progesterone receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, respectively. AL-438 shows antiinflammatory activity .

HY-106256

HMR-3339	Estrogen Receptor/ERR	Metabolic Disease Endocrinology
HMR-3339 is a new selective **estrogen receptor** modulator. HMR-3339 reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine. HMR-3339 corrects bone alterations induced by ovariectomy .

HY-127133

Methylpiperidino pyrazole MPP	Estrogen Receptor/ERR	Endocrinology
Methylpiperidino pyrazole (MPP) is a potent and selective ER (estrogen receptor) modulator. Methylpiperidino pyrazole induces significant apoptosis in the endometrial cancer and oLE cell lines. Methylpiperidino pyrazole reverses the the positive effects of beta-estradiol. Methylpiperidino pyrazole has mixed agonist/antagonist action on murine uterine ERalpha in vivo .

HY-125037

Diptoindonesin G	Estrogen Receptor/ERR HSP	Cancer
Diptoindonesin G is a 2-arylbenzofuran derivative and a modulator of **estrogen receptor and HSP90 middle domain. Diptoindonesin G exhibits strong cytotoxicity against mouse leukemia P-388 cells with an IC₅₀** of 13.2 μM. Diptoindonesin G has antitumor activity and can be used in the research of tumors such as breast cancer .

HY-16950AR

(E/Z)-4-Hydroxytamoxifen (Standard) Afimoxifene (Standard); 4-OHT (Standard)	Reference Standards Estrogen Receptor/ERR Endogenous Metabolite	Cancer
(E/Z)-4-Hydroxytamoxifen (Standard) is the analytical standard of (E/Z)-4-Hydroxytamoxifen. This product is intended for research and analytical applications. (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective **estrogen receptor** modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity .

HY-122359B

Levormeloxifene fumarate L-Centchroman fumarate; L-Ormeloxifene fumarate	Estrogen Receptor/ERR	Others
Levormeloxifene (fumarate) is a stable salt form of Levormeloxifene. Levormeloxifene (fumarate) is an **estrogen receptor** modulator that plays an important role in prevention of postmenopausal bone loss .

HY-107045

CHF 4227 free base	Estrogen Receptor/ERR	Endocrinology
CHF 4227 free base is an orally active and selective **estrogen receptor** modulator (SERM) with high affinity to the human estrogen receptor-α and -β (K_i values of 0.017 nM and 0.099 nM, respectively) .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-16950A

(E/Z)-4-Hydroxytamoxifen 3 Publications Verification Afimoxifene; 4-OHT	Alkaloids Monophenols Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Estrogen Receptor/ERR Adhesion G Protein-coupled Receptors (AGPCRs) Drug Metabolite
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective **estrogen receptor** modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity .

HY-N2371

27-Hydroxycholesterol 5+ Cited Publications 27-OHC	Structural Classification Classification of Application Fields Disease markers Nervous System Disorder Endogenous metabolite Disease Research Fields Cardiovascular System Disorder Steroids Source Classification Cancer	Estrogen Receptor/ERR LXR Endogenous Metabolite
27-Hydroxycholesterol (27-OHC) is a selective **estrogen receptor** modulator and an agonist of the liver X receptor.

HY-13738A

Raloxifene hydrochloride Maximum Cited Publications 19 Publications Verification Keoxifene hydrochloride; LY156758; LY139481 hydrochloride	Alkaloids Piperidine Alkaloids Classification of Application Fields Rutaceae Phenols Polyphenols Plants Disease Research Fields Tetradium ruticarpum (A. Jussieu) T. G. Hartley Endocrinology Source Classification Cancer	Estrogen Receptor/ERR Autophagy
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-15731

Estetrol	Cardiovascular Disease Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Steroids Source Classification	Estrogen Receptor/ERR Endogenous Metabolite NO Synthase
Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-126109

(±)-8-Prenylnaringenin	Structural Classification Flavonoids Humulus lupulus L. Flavonones Plants Moraceae Source Classification	Estrogen Receptor/ERR Apoptosis
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen *Receptor/ERR) that inhibits ERα* and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-13738AR

Raloxifene hydrochloride (Standard) 5+ Cited Publications Keoxifene hydrochloride(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)	Alkaloids Classification of Application Fields Rutaceae Phenols Plants Disease Research Fields Tetradium ruticarpum (A. Jussieu) T. G. Hartley Endocrinology Source Classification Cancer	Reference Standards Estrogen Receptor/ERR Autophagy
Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .

HY-N2371R

27-Hydroxycholesterol (Standard) 27-OHC (Standard)	Structural Classification Natürliche Produkte Disease markers Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Source Classification	Reference Standards Estrogen Receptor/ERR LXR Endogenous Metabolite
27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the liver X receptor.

HY-N11785

Glyceollin I	Structural Classification Monophenols Leguminosae Glycine max (L.) merr Phenols Plants Source Classification	Estrogen Receptor/ERR
Glyceollin I is a selective estrogen receptor (ER) modulator with anticancer, antioxidant, and anti-inflammatory activities. Glyceollin I is promising for research of estrogen-related cancers (e.g., breast, ovarian) and metabolic disorders (e.g., hypercholesterolemia) .

HY-125037

Diptoindonesin G	Structural Classification Phenols Polyphenols Plants Dipterocarpaceae Source Classification	Estrogen Receptor/ERR HSP
Diptoindonesin G is a 2-arylbenzofuran derivative and a modulator of **estrogen receptor and HSP90 middle domain. Diptoindonesin G exhibits strong cytotoxicity against mouse leukemia P-388 cells with an IC₅₀** of 13.2 μM. Diptoindonesin G has antitumor activity and can be used in the research of tumors such as breast cancer .

HY-16950AR

(E/Z)-4-Hydroxytamoxifen (Standard) Afimoxifene (Standard); 4-OHT (Standard)	Structural Classification Alkaloids Monophenols Other Alkaloids Phenols Endogenous metabolite Source Classification	Reference Standards Estrogen Receptor/ERR Endogenous Metabolite
(E/Z)-4-Hydroxytamoxifen (Standard) is the analytical standard of (E/Z)-4-Hydroxytamoxifen. This product is intended for research and analytical applications. (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective **estrogen receptor** modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity .

HY-N1556

Psidial A	Natürliche Produkte Psidium guajava Linn. Myrtaceae Plants Source Classification	Estrogen Receptor/ERR
Psidial A is an epimer of sesquiterpenoid-diphenylmethane meroterpenoid. Psidial A may act as a selective estrogen receptors modulator. Psidial A also has potential for anticancer research .

HY-131586

3,7-Dihydroxyflavone Resogalangin	Flavonoids Flavones Plants Fabaceae Zuccagnia punctata Cav. Source Classification	17β-HSD Estrogen Receptor/ERR Aldose Reductase
3,7-Dihydroxyflavone (Resogalangin) is a flavonoid phytoestrogen, which can be isolated from Adenophora species. 3,7-Dihydroxyflavone is a modulator of **estrogen receptors and an inhibitor of human progesterone metabolizing enzyme AKR1C1 and fungal 17β-hydroxysteroid dehydrogenase and a redox inhibitor (IC₅₀=0.6 and 6.0 μM, respectively). 3,7-Dihydroxyflavone is a fluorescent binding substrate for human serum albumin (HSA)** with excitation wavelengths of 370 nm (pH 7.4) and 350 nm (pH 3.5), respectively, and emission wavelength of 515 nm .

HY-N17632

Moracin G	Structural Classification Phenols Polyphenols Plants Moraceae Morus alba Linn. Source Classification	Estrogen Receptor/ERR Akt MELK COX Apoptosis
Moracin G is a plant-derived kinase modulator and receptor ligand that forms stable bindings with multiple key proteins (AKT1, COX2 and Estrogen receptor 1) and competitively inhibits the activity of specific kinases. By binding to MELK to disrupt cell cycle regulation, Moracin G impairs the survival and proliferation of cancer cells, induces cancer cell apoptosis, and thereby exerts anti-tumor potential. Moracin G can be used in research related to periodontitis and breast cancer .

Art. -Nr.	Produktname	Chemical Structure

HY-13757AS

Tamoxifen-d5
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity .

HY-16950BS

(E)-4-Hydroxytamoxifen-d5
(E)-4-Hydroxytamoxifen-d5 ((E)-Afimoxifene-d5) is the deuterium labeled (E)-4-Hydroxytamoxifen. (E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an **estrogen receptor** modulator.

HY-13757S

Tamoxifen-d3 hydrochloride

Tamoxifen-d₃ hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-B0723S2

Ospemifene-d5
Ospemifene-d₅ (FC-1271a-d₅) is deuterium labeled Ospemifene. Ospemifene is a non-estrogen selective **estrogen receptor** modulator (SERM), with K_is of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer .

HY-13738S2

Raloxifene-d4 hydrochloride
Raloxifene-d₄ (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-13738S

Raloxifene-d4
Raloxifene-d₄ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-13738S3

Raloxifene-d10
Raloxifene-d₁₀ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-15731S

Estetrol-d4
Estetrol-d₄ is the deuterium labeled Estetrol. Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast .

HY-B0723S

Ospemifene-d4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC₅₀ values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects .

HY-W727814

Pipendoxifene-d10
Pipendoxifene-d₁₀ (ERA-923-d₁₀) is the deuterium labeled Pipendoxifene (HY-13724). Pipendoxifene is a selective estrogen receptor modulator (SERM).

HY-B2158S

Chlorotrianisene-d9
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium

Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S

Raloxifene 4'-glucuronide-d4

Raloxifene 4'-glucuronide-d₄ is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-15731S1

Estetrol-d4 (Major)

Estetrol-d₄ (Major) is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-B0005AS

Toremifene-d6
Toremifene-d₆ is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 μM and 2.6 μM, respectively .

HY-79576S2

Estrone 3-methyl ether-13C6
Estrone 3-methyl ether- ¹³C₆ is a ¹³C-labeled Estrone 3-methyl ether (HY-79576). Estrone 3-methyl ether (Oestrone methyl ether; 3-O-Methylestrone) is a synthetic intermediate useful for synthesis of estrogen receptor modulator .

HY-B0005S1

Toremifene-d6 hydrochloride
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-B0005S

Toremifene-d6 citrate
Toremifene-d₆ (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 μM and 2.6 μM, respectively .

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .

HY-W778408

Tamoxifen-13C6

Tamoxifen- ¹³C₆ (ICI 47699- ¹³C₆) is the ¹³C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .

HY-A0031S

Bazedoxifene-d4

Bazedoxifene-d₄ is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

HY-A0031S2

Bazedoxifene-d4 acetate

Bazedoxifene-d₄ (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].

HY-W744272

Estetrol-d3

Estetrol-d₃ is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear?estrogen receptor?modulator. Estetrol binds?ERα?as well as?ERβ?(with a fourfold lower affinity). Estetrol increases?eNOS?expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research.

Art. -Nr.	Compare	Produktname	Application	Reactivity	Image

HY-P83728

	PGC1 alpha+beta Antibody (YA3458) LEM6 antibody; Ligand effect modulator 6 antibody; PERC antibody; Peroxisome proliferative activated receptor, gamma, coactivator 1 antibody; PGC 1 alpha antibody; PGC-1-beta antibody; PGC-1-related estrogen receptor alpha coactivator antibody; PGC1 antibody; PGC1A antibody; PGC1v antibody; PPAR gamma coactivator 1 alpha antibody; PPAR gamma coactivator-1 beta antibody; PPARGC 1 alpha antibody; PPARGC-1-beta antibody; PPARGC1 antibody; PPARGC1A antibody; Ppargc1b antibody; PRGC1_HUMAN antibody; PRGC2_HUMAN antibody;	WB	Human, Mouse, Rat
	PGC1 alpha+beta Antibody (YA3458) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha+beta.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname		Classification

HY-N2371

27-Hydroxycholesterol 5+ Cited Publications 27-OHC		Cholesterol
27-Hydroxycholesterol (27-OHC) is a selective **estrogen receptor** modulator and an agonist of the liver X receptor.

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

estrogen receptor modulator

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products